Ian Linney has led integrated drug discovery projects which have delivered multiple preclinical candidates in respiratory and immuno-oncology indications. He has expertise in all areas of drug discovery, and is currently instigating programs targeting the central nervous system (CNS) and hematological indications. Ian manages programs across many areas, ensuring scientific integration across disciplines such as chemistry and biology.
He previously worked at the James Black Foundation, where he was heavily involved in the development of molecules to target multiple GPCR targets, leading to multiple preclinical candidates including a clinical candidate.
Dr. Linney obtained both his Bachelor of Science and Doctor of Philosophy from the University of Bath and conducted post-doctoral work at the Novartis Institute of Medical Sciences in London working on the synthesis and pharmacology of Epibatidine.